Your browser is no longer supported. Please, upgrade your browser.
Settings
IGMS IGM Biosciences, Inc. daily Stock Chart
IGMS [NASD]
IGM Biosciences, Inc.
Index- P/E- EPS (ttm)-1.73 Insider Own1.60% Shs Outstand30.49M Perf Week-7.66%
Market Cap1.84B Forward P/E- EPS next Y-3.16 Insider Trans4.25% Shs Float13.38M Perf Month7.53%
Income-52.80M PEG- EPS next Q-0.65 Inst Own56.60% Short Float4.97% Perf Quarter-5.20%
Sales- P/S- EPS this Y-80.00% Inst Trans5.46% Short Ratio7.02 Perf Half Y169.34%
Book/sh7.35 P/B8.14 EPS next Y-18.50% ROA-25.70% Target Price61.33 Perf Year-
Cash/sh6.74 P/C8.88 EPS next 5Y- ROE-33.10% 52W Range16.10 - 74.13 Perf YTD56.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-19.30% Beta-
Dividend %- Quick Ratio28.20 Sales past 5Y- Gross Margin- 52W Low271.55% ATR4.90
Employees77 Current Ratio28.20 Sales Q/Q- Oper. Margin- RSI (14)50.68 Volatility6.91% 9.36%
OptionableNo Debt/Eq0.00 EPS Q/Q-7.30% Profit Margin- Rel Volume0.75 Prev Close58.40
ShortableYes LT Debt/Eq0.00 EarningsMar 26 AMC Payout- Avg Volume94.77K Price59.82
Recom1.20 SMA20-0.31% SMA504.25% SMA20051.02% Volume70,881 Change2.43%
May-28-20Initiated SunTrust Buy $86
Apr-22-20Initiated Wedbush Outperform $73
Oct-14-19Initiated Stifel Buy $32
Oct-14-19Initiated Piper Jaffray Overweight $26
Oct-14-19Initiated Jefferies Buy $25
Oct-14-19Initiated Guggenheim Buy $30
May-28-20 07:00AM  
May-12-20 07:00AM  
May-07-20 04:03PM  
12:25PM  
Apr-29-20 04:05PM  
Apr-03-20 07:00AM  
Mar-26-20 04:05PM  
02:30PM  
Mar-19-20 07:00AM  
Mar-04-20 07:00AM  
Feb-06-20 07:00AM  
Jan-07-20 07:00AM  
Dec-22-19 01:29PM  
Nov-12-19 07:00AM  
Nov-07-19 05:04PM  
Nov-01-19 10:24AM  
Oct-02-19 07:00AM  
Sep-20-19 04:05PM  
Sep-18-19 11:03AM  
07:39AM  
Sep-17-19 08:46PM  
04:04PM  
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEHRENS M KATHLEENDirectorDec 09Buy24.8720,000497,31610,000Dec 11 07:04 PM